There are expectations that another vaccine will be put into the field next month in the United States, which has been vaccinated after Modena after Pfizer. The’third candidate’, which is most often discussed, is a vaccine being developed by Janssen, a subsidiary of Johnson & Johnson in the United States.
In an interview with ABC Broadcasting on the 20th (local time), US Assistant Secretary of Health Brett Girore said, “Jansen will request approval for emergency use of the Corona 19 vaccine in January.” “We will go through all of the established procedures transparently, and we do not know the results yet,” he said. “We are expecting to have at least three vaccines by January.”
Janssen’s vaccine is a vaccine that the Korean government has also announced to conclude a supply contract within this year.
One of the characteristics that differs from other vaccines is that they only need to be hit once. Most of the COVID-19 vaccines, such as Pfizer, Modena, and AstraZeneca, require two doses to be effective.
It is similar to AstraZeneca in that it is a viral vector vaccine that injects a harmless virus into the human body. It can be stored at room temperature, making it easy to distribute.
On the other hand, Pfizer and Moderna vaccine is a’nucleic acid vaccine’ that induces antibody formation by putting messenger RNA (mRNA) in the body, not a virus. The distribution process is also tricky as it must be stored at -70 degrees and -20 degrees respectively.
The cost of a single dose of Janssen vaccine is 1,900 won, which is cheaper than Pfizer Modena vaccine and more expensive than AstraZeneca vaccine.
However, the Janssen vaccine is still undergoing phase 3, which is the final stage of clinical trials. The results are expected to come out next month, which is expected to be the final gateway to obtaining approval for emergency use.
Previously, the Janssen Vaccine Phase III was once stopped in October for the reason that “the participant has developed an unknown disease,” and then resumed in early November.
According to a summary of the Global Health Innovation Center at Duke University, as of the 18th, 374 million doses of Janssen vaccine were contracted or purchased. In addition to Korea (4 million times), EU 200 million times, US 100 million times, UK 30 million times, Canada 38 million times, New Zealand 2 million times, etc.
In addition to the Janssen vaccine, Vice Minister Giroer added that other vaccine candidates are preparing for urgent use approval screening. He said, “I am confident that anyone who wishes to get a vaccination in the US by next June will get a chance to get it.”
Reporter Lim Sun-young [email protected]